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Material and Methods: Retrospective review of all patients 
with T4 HNSCC treated with IMRT at our centre, between 
December 2010 and February 2013. Overall, relapse free and 
local relapse-free survival were calculated from date of 
biopsy to date of death, relapse or last follow up. 
 
Results: Of the 69 patients with T4 tumours, 73.9% were 
male and median age was 69 (41-84). 50.7% were 
oropharyngeal tumours and 73.9% were node positive. 
Primary resection was performed in 18 patients. Eighteen 
patients underwent radiotherapy alone and 51 received 
concurrent chemotherapy (45 cisplatin, 6 cetuximab). Median 
follow up was 3.0 years (range = 3 months to 3.9 years). 28 
patients died; 22 related to HNSCC, 6 from other causes. 
Overall survival at 3 years was 58.0% (95% CI: 44.6 to 69.1). 
28 patients (40.6%), relapsed with median time to relapse of 
8 months. 20 patients (29.0%) relapsed locoregionally and 11 
patients (15.9%) developed distant metastatic disease. For 8 
patients, distant metastases were the only site of relapse. 
Surgical salvage was performed in 6 patients with 
locoregional relapse only, 2 of whom have since died from 
causes related to HNSCC. Relapse free survival at 3 years was 
54.0% (95% CI: 40.5 to 65.8) and loco-regional relapse free 
survival at 3 years was 65.5% (95% CI: 51.2 to 76.5). Nineteen 
patients (27.5%) had residual disease on PET scan 12 weeks 
post treatment. These patients were at greater risk of 
relapse and death with 3 year overall survival of 37.0% (95% 
CI 15.4 to 59.0) and 3 year relapse free survival of 40.5% 
compared to 3 year overall survival of 85.7% (53.9 to 96.2) 
and 3 year relapse free survival of 79.0% (47.9 to 92.7) in 
patients with normal PET scans.  
 
Conclusion: There is a significant risk of relapse and death in 
T4 HNSCC tumours, particularly in those with residual disease 
following radiotherapy. However, IMRT, either alone or in 
combination with chemotherapy or surgery, achieved 3 year 
locoregional control of 65.5% (95% CI 51.2%-76.5%). This is a 
meaningful local control rate for locally advanced disease in 
which local relapse confers significant morbidity. 
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Purpose or Objective: To investigate the role of HPV status, 
comorbidity and polypharmacy on outcomes of elderly 
patient with oropharyngeal carcinoma (OPC). 
 
Material and Methods: We retrospectively reviewed a 
prospectively compiled cohort of elderly patients (>70 years) 
with newly diagnosed OPC treated with curative radiotherapy 
(RT)+/- systemic therapy in 2000-2013. Tumor HPV status was 
assessed by p16 staining. Comorbidities were quantified by 
Charlson Comorbidity Index (CCI). The Comorbidity-
Polypharmacy Score (CPS), a validated predictor of outcome 
for older trauma patients, was used to take into account the 
number of medications as a surrogate of the severity of 
comorbidities. Overall survival (OS), and relapse-free survival 
(RFS) were calculated and compared between HPV-positive 
[HPV(+)] and HPV-negative [HPV(-)] cohort. Two multivariate 
analysis (MVA) models [one included CCI (MVA-CCI), one 
included CPS (MVA-CPS)] were used to confirm the prognostic 
value of HPV, CCI or CPS, pack-year (PY) smoking, ECOG 
performance status (PS), and age for OS adjusted for disease 
extent (T, N). 
 
Results: Tumor HPV status was ascertained in 229 of 287 
(80%) patients revealing 115 HPV(+) and 114 HPV(-). Median 
age was 74.8 years (range 70-93). Systemic agents were given 
in 48 (21%) patients [chemo 17; EGFR inhibitor 31). RT 
incompletion [5 (4%) vs 8 (7%), p=0.41) and unplanned RT 
break rates [22 (19%) vs 28 (25%), p=0.34] were similar 
between HPV(+) vs HPV(-) cohorts. No significant difference 
in distribution of CCI (p=0.30) or CPS score (p=0.22) between 
HPV(+) vs HPV(-) cases. CCI and CPS have a moderate 
correlation (Kappa: 0.51). Median follow-up was 4.6 years. 
HPV(+) patients had better 5-year OS (59% vs 32%, p<0.001) 
and RFS (75% vs 54%, p<0.001) compared to HPV(-). MVA 
adjusted for T and N-category confirmed HPV(+) status was 
the strongest prognostic factor (PF) for OS [MVA-CCI: HR 0.52 
(95% CI 0.34-0.79), p=0.002; MVA-CPS: HR 0.56 (0.36-0.85), 
p=0.007]. CPS was also a PF for OS [HR 1.05 (1.00-1.11), 
p=0.044]. CCI was not significant (p=0.17). ECOG PS was also 
a PF [MVA-CCI: HR 2.31; MVA-CPS: HR 2.32, both p<0.001]. 
Smoking (>20 PY) was prognostic in MVA-CCI (HR 1.62, 
p=0.035) and marginally prognostic in MVA-CPS (HR 1.56, 
p=0.056). Age was not significant in MVA-CCI (p=0.16) or 
MVA-CPS (p=0.65) models. 
 
Conclusion: In elderly patients with OPC, HPV status is a 
strong PF for OS. Neither chronologic age nor CCI is 
prognostic. Higher CPS is correlated with poorer OS, which 
implies that inclusion of polypharmacy in addition to 
comorbidity might be a better reflection of competing 
mortality risk in this population, and attention to competing 
mortality causes may influence outcome for this complex 
patient group. Further validation of prognostication of CPS in 
elderly OPC population is warranted. 
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Purpose or Objective: While the total tumor volume(TTV) 
has been extensively analyzed in literature as a prognostic 
factor in head and neck cancer, there exist no studies to date 
that have analysed the impact of TTV on response to chemo 
radiation(CCRT), particularly from the Indian subcontinent 
and in patients treated with IMRT. We did a prospective study 
that attempted to elucidate the role of total tumor volume 
as a prognostic factor in locally advanced oropharyngeal and 
hypopharyngeal cancer. 
 
Material and Methods: We enrolled 87 patients of Stage III-IV 
cancer of the oropharynx(57),and hypopharynx(30) , who 
received definitive CCRT with IMRT. The TTV was the sum of 
the gross tumour volume and the nodal volume delineated on 
the planning CT scan. The impact of TTV on Locoregional 
relapse free survival (LRFS), response to chemoradiation (RR) 
and overall survival (OS) was assessed over a follow up of 2 
years. Survival analysis was by kaplan meir method with log 
rank testing for assessing significance between groups 
Univariate analysis was by mann-whitney/chi square test 
,multivariate analysis was by logistic regression forward 
stepwise method and a model to predict response was 
generated .ROC curve analysis was done for calculating cut 
offs. A classification tree for Response was generated using 
CART analysis (CHAID method). 
 
Results: The 2 year OS, LRFS, and RR were 64%, 56% & 65%. 
The T stage distribution was T2(5) , T3(42) ,T4(42) & N stage 
was N0 (11),N1(28),N2A(10),N2B (17),N2C(17) & N3(4).The 
mean TTV was 67.4 cc (8-191 )cc. The mean TTV in 
Responders/ non responders was 51.9 cc / 95.5cc.On 
multivariate analysis, the TTV was a significant prognostic 
factor for RR & LRFS but not for OS. ROC curve analysis found 
cut off of 48 cc for RR with AUC of 0.778(0.672-0.884) ans 
sensitivity/specificity of 87% /60%.The RR for the <48cc and 
